195 related articles for article (PubMed ID: 35065301)
1. Season, weight, and age, but not transmissible cancer, affect tick loads in the endangered Tasmanian devil.
Belkhir S; Hamede R; Thomas F; Ujvari B; Dujon AM
Infect Genet Evol; 2022 Mar; 98():105221. PubMed ID: 35065301
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of Cryptosporidium and Giardia from the Tasmanian devil (Sarcophilus harrisii).
Wait LF; Fox S; Peck S; Power ML
PLoS One; 2017; 12(4):e0174994. PubMed ID: 28423030
[TBL] [Abstract][Full Text] [Related]
3. Transmissible cancer influences immune gene expression in an endangered marsupial, the Tasmanian devil (Sarcophilus harrisii).
Raven N; Klaassen M; Madsen T; Thomas F; Hamede RK; Ujvari B
Mol Ecol; 2022 Apr; 31(8):2293-2311. PubMed ID: 35202488
[TBL] [Abstract][Full Text] [Related]
4. Curse of the devil: molecular insights into the emergence of transmissible cancers in the Tasmanian devil (Sarcophilus harrisii).
Patchett AL; Flies AS; Lyons AB; Woods GM
Cell Mol Life Sci; 2020 Jul; 77(13):2507-2525. PubMed ID: 31900624
[TBL] [Abstract][Full Text] [Related]
5. Density trends and demographic signals uncover the long-term impact of transmissible cancer in Tasmanian devils.
Lazenby BT; Tobler MW; Brown WE; Hawkins CE; Hocking GJ; Hume F; Huxtable S; Iles P; Jones ME; Lawrence C; Thalmann S; Wise P; Williams H; Fox S; Pemberton D
J Appl Ecol; 2018 May; 55(3):1368-1379. PubMed ID: 30089931
[TBL] [Abstract][Full Text] [Related]
6. Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations.
Kreiss A; Brown GK; Tovar C; Lyons AB; Woods GM
Vaccine; 2015 Jun; 33(26):3016-25. PubMed ID: 25708088
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.
Pye R; Hamede R; Siddle HV; Caldwell A; Knowles GW; Swift K; Kreiss A; Jones ME; Lyons AB; Woods GM
Biol Lett; 2016 Oct; 12(10):. PubMed ID: 28120799
[TBL] [Abstract][Full Text] [Related]
8. Complex associations between cancer progression and immune gene expression reveals early influence of transmissible cancer on Tasmanian devils.
Raven N; Klaassen M; Madsen T; Jones M; Hamilton DG; Ruiz-Aravena M; Thomas F; Hamede RK; Ujvari B
Front Immunol; 2024; 15():1286352. PubMed ID: 38515744
[TBL] [Abstract][Full Text] [Related]
9. Isotopic niche variation in Tasmanian devils
Bell O; Jones ME; Cunningham CX; Ruiz-Aravena M; Hamilton DG; Comte S; Hamede RK; Bearhop S; McDonald RA
Ecol Evol; 2021 Jun; 11(12):8038-8053. PubMed ID: 34188870
[TBL] [Abstract][Full Text] [Related]
10. Evolution in a transmissible cancer: a study of the chromosomal changes in devil facial tumor (DFT) as it spreads through the wild Tasmanian devil population.
Pearse AM; Swift K; Hodson P; Hua B; McCallum H; Pyecroft S; Taylor R; Eldridge MD; Belov K
Cancer Genet; 2012 Mar; 205(3):101-12. PubMed ID: 22469509
[TBL] [Abstract][Full Text] [Related]
11. Heat shock proteins expressed in the marsupial Tasmanian devil are potential antigenic candidates in a vaccine against devil facial tumour disease.
Tovar C; Patchett AL; Kim V; Wilson R; Darby J; Lyons AB; Woods GM
PLoS One; 2018; 13(4):e0196469. PubMed ID: 29702669
[TBL] [Abstract][Full Text] [Related]
12. Infectious disease and sickness behaviour: tumour progression affects interaction patterns and social network structure in wild Tasmanian devils.
Hamilton DG; Jones ME; Cameron EZ; Kerlin DH; McCallum H; Storfer A; Hohenlohe PA; Hamede RK
Proc Biol Sci; 2020 Dec; 287(1940):20202454. PubMed ID: 33290679
[TBL] [Abstract][Full Text] [Related]
13. Tracing the rise of malignant cell lines: Distribution, epidemiology and evolutionary interactions of two transmissible cancers in Tasmanian devils.
James S; Jennings G; Kwon YM; Stammnitz M; Fraik A; Storfer A; Comte S; Pemberton D; Fox S; Brown B; Pye R; Woods G; Lyons B; Hohenlohe PA; McCallum H; Siddle H; Thomas F; Ujvari B; Murchison EP; Jones M; Hamede R
Evol Appl; 2019 Oct; 12(9):1772-1780. PubMed ID: 31548856
[TBL] [Abstract][Full Text] [Related]
14. Immunoglubolin dynamics and cancer prevalence in Tasmanian devils (Sarcophilus harrisii).
Ujvari B; Hamede R; Peck S; Pemberton D; Jones M; Belov K; Madsen T
Sci Rep; 2016 Apr; 6():25093. PubMed ID: 27126067
[TBL] [Abstract][Full Text] [Related]
15. Allorecognition in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species with limited genetic diversity.
Kreiss A; Cheng Y; Kimble F; Wells B; Donovan S; Belov K; Woods GM
PLoS One; 2011; 6(7):e22402. PubMed ID: 21811598
[TBL] [Abstract][Full Text] [Related]
16. Trophic cascades following the disease-induced decline of an apex predator, the Tasmanian devil.
Hollings T; Jones M; Mooney N; McCallum H
Conserv Biol; 2014 Feb; 28(1):63-75. PubMed ID: 24024987
[TBL] [Abstract][Full Text] [Related]
17. Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.
Tovar C; Pye RJ; Kreiss A; Cheng Y; Brown GK; Darby J; Malley RC; Siddle HV; Skjødt K; Kaufman J; Silva A; Baz Morelli A; Papenfuss AT; Corcoran LM; Murphy JM; Pearse MJ; Belov K; Lyons AB; Woods GM
Sci Rep; 2017 Mar; 7():43827. PubMed ID: 28276463
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and carboplatin trials in Tasmanian devils (Sarcophilus harrisii) with Tasmanian devil facial tumor disease.
Phalen DN; Frimberger AE; Peck S; Pyecroft S; Harmsen C; Lola S; Moore AS
Vet J; 2015 Dec; 206(3):312-6. PubMed ID: 26538144
[TBL] [Abstract][Full Text] [Related]
19. Transmissible cancer and longitudinal telomere dynamics in Tasmanian devils (Sarcophilus harrisii).
Madsen T; Klaassen M; Raven N; Dujon AM; Jennings G; Thomas F; Hamede R; Ujvari B
Mol Ecol; 2022 Dec; 31(24):6531-6540. PubMed ID: 36205590
[TBL] [Abstract][Full Text] [Related]
20. Devil Facial Tumor Disease.
Pye RJ; Woods GM; Kreiss A
Vet Pathol; 2016 Jul; 53(4):726-36. PubMed ID: 26657222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
